Pharsight

Forteo generic

Forteo is an Osteoporosis drug owned by Lilly. The active ingredient in Forteo is teriparatide. The drug was first authorized for market use on 26th November, 2002. Forteo is available in solution form for subcutaneous administration.

When will Forteo generic be available?

The generics of Forteo are expected to be released after 25th March, 2025. This is due to the expiry of the patent US7517334, titled 'Medication dispensing apparatus with spring-driven locking feature enabled by administration of final dose.' It's worth noting that a Para IV filing could potentially expedite the generic release prior to this date.

Forteo uses

Forteo, with its active ingredient teriparatide, is primarily used in the treatment of Osteoporosis. teriparatide works by stimulating new bone formation, thereby strengthening the skeletal system and reducing the risk of fractures.

Forteo patent expiration

Forteo is protected by one patent. The last patent, which is US7517334, is set to expire on 25th March, 2025. Once expired, it will open the possibility for the release of Forteo generics. Below are the details of the patent:

Forteo dosage

Want to ask something?